Cannabinoids Data Events Reference 
Cannabis Law Report
DECEMBER 7, 2021
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, 0.59, 95% CI [0.36–0.97]),
Cannabis Law Report
DECEMBER 14, 2021
(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. Safety and Tolerability (S&T) was assessed by asking participants to record Adverse Events (AEs).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 23, 2021
The FDA and CDC each issued warning notices to the public regarding delta-8 THC products on September 14, 2021, many of which are marketed as hemp products (and include some non-obvious references to other novel cannabinoids that may have similar effects and marketing). Delta-8 THC has psychoactive and intoxicating effects.
Veriheal
SEPTEMBER 15, 2021
Much of the earlier research on cannabis thus belongs to this type of research as it sought to establish a frame of reference and to generate hypotheses. . Non-Experimental Research: Observational study, or non-experimental research, focuses on analyzing data in its natural context.
Cannabis Law Report
JANUARY 23, 2022
Events like these afford us a glimpse into the future of research and medicine in this field. This brings us to one of the most powerful medical studies that demonstrate the therapeutic potential of cannabinoids. CBD was also well tolerated by patients with no severe adverse events due to its consumption being reported.
The Cannigma
OCTOBER 9, 2021
Studies demonstrate that cannabis and its cannabinoid constituents have an implication on human urinary function. The common understanding is that every individual has a separate and different reaction to cannabinoid-based therapy, the same is true with how it might influence individual urinary symptoms.
CannaMD
DECEMBER 9, 2020
Noting that the effects of oral administration of cannabis (edibles) can be less predictable that smoked or vaporized administration of products with similar levels of specific cannabinoids, the AHA cautions: Patients must be made aware that the onset of effects begins within 30 minutes to ?1 CANNABIS: POTENTIAL AND KNOWN BENEFITS.
Expert insights. Personalized for you.
52 
Let's personalize your content